Positive Response to Salbutamol Inhalation in Cystic Fibrosis Patients

A Swiss study recently published in Respiration found that salbutamol inhalation had a positive short-term effect on forced expiratory volume in pediatric patients with cystic fibrosis (CF).

The use of salbutamol as a bronchodilator is controversial due to a lack of evidence showing a positive effect. In this study, researchers hypothesized that novel diagnostic tests such as multiple-breath washout and functional MRI could better elucidate such bronchodilator effects.

The researchers therefore conducted a prospective, single-center study of 30 children (aged 6 to 18 years; mean age, 12.5 years) with stable CF to assess functional response to nebulized inhalation with salbutamol, using pulmonary function tests, multiple-breath washout, and matrix pencil-MRI before and after the salbutamol treatment to measure functional response.

Test results indicated that lung clearance index improved marginally (P =.111) after nebulized inhalation with salbutamol.

Get the full story at pulmonologyadvisor.com.

Salbutamol Inhalation Cystic Fibrosis

Go To Source For Respiratory Therapy Coverage

RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.

Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry. Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.